Geron's imetelstat MAA for lower-risk MDS validated by EMA for review

GERON CORP

MAA for imetelstat in transfusion-dependent anemia with lower-risk MDS validated by EMA.
Review by CHMP under centralized procedure covering all 27 EU states plus Iceland, Norway, Liechtenstein.
Expected review period of approximately 14 months.
Submission made in September 2023; now under regulatory review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.